Form 4: Immuneering Director Peter Feinberg Receives Stock Options

Director Peter Feinberg was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Summary

• Director Peter Feinberg acquired 33,350 stock options in Immuneering Corp (IMRX).
• The options have an exercise price of $4.12 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant signal regarding company performance.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of new options results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the underlying Class A Common Stock.
• Potential for future dilution of equity.

Future Outlook

The options vest in equal monthly installments over one year, becoming fully vested by June 11, 2027, or the date of the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board expertise, though they remain subject to shareholder scrutiny regarding dilution.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for small-cap biotech firms.
• Vesting schedules of one year for director equity are relatively aggressive compared to the multi-year vesting often seen in executive compensation packages.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options to commence on July 11, 2026.
• Full vesting expected by June 11, 2027.

Key Dates

Keywords

Immuneering, IMRX, Form 4, Director Compensation, Stock Options, Insider Trading